What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Niraparib demonstrates a clear clinical advantage with significant improvement in progression-free survival compared to placebo in both BRCA mutation-positive and negative subgroups. The median progression-free survival was 21 months for BRCA mutation-positive patients and 9.3 months for those without, with hazard ratios indicating substantial efficacy. However, the uncertainty regarding overall survival for non-BRCA patients prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for niraparib fall within the range typically considered cost-effective for Healthcare resources, with ICERs reported at £22,185 per QALY for BRCA mutation-positive patients and within the £20,000 to £30,000 range for those without. This indicates a strong economic value proposition.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that niraparib may improve quality of life by delaying disease progression, which is highly valued by patients. The clinical expert noted that maintenance therapy with niraparib can positively affect mental health, although the trial data did not fully capture this benefit. The overall impact on HRQoL appears positive but is based on moderate evidence.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Niraparib has an acceptable safety profile, with adverse events primarily being mild to moderate. The committee noted that while there are concerns regarding toxicity, these are manageable and do not significantly undermine the treatment’s overall value.
Was the drug compared against what payers expect? — Comparator Selection
Niraparib was compared against placebo in a well-designed RCT (NOVA), which is appropriate for assessing its efficacy. The committee acknowledged that while there are limitations in the overall trial population, the use of placebo as a comparator is standard practice.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included patients with both BRCA mutation-positive and negative statuses, which reflects the intended real-world patient population. However, the committee noted that the overall trial population may not be fully representative for decision-making, particularly regarding the BRCA-negative subgroup.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Niraparib can be integrated into existing treatment pathways with minor adjustments, as it is a maintenance therapy following platinum-based chemotherapy. The committee noted that the treatment aligns well with current clinical practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of niraparib are manageable, with the potential for cost savings due to reduced need for subsequent chemotherapy. The committee recognized that while there is a notable cost burden, it is justifiable given the treatment’s benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a robust RCT (NOVA) with additional data collected over time. However, there are some methodological concerns regarding the overall survival data, particularly for the non-BRCA subgroup, which introduces some uncertainty.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there is some uncertainty regarding the overall survival benefit for non-BRCA patients, the treatment addresses a significant unmet need in maintenance therapy for ovarian cancer. The committee noted that the societal context supports the use of niraparib.
